Krystal Biotech (NASDAQ:KRYS) Now Covered by Jefferies Financial Group

Analysts at Jefferies Financial Group started coverage on shares of Krystal Biotech (NASDAQ:KRYS) in a report released on Wednesday, MarketBeat reports. The brokerage set a “buy” rating and a $245.00 price target on the stock. Jefferies Financial Group’s price target indicates a potential upside of 36.93% from the stock’s previous close.

Several other equities analysts have also recently issued reports on KRYS. HC Wainwright reaffirmed a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research note on Friday, February 28th. Chardan Capital lifted their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. Citigroup lifted their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research report on Thursday, February 20th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Krystal Biotech in a research report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $220.00.

Krystal Biotech Trading Down 0.6 %

KRYS stock opened at $178.93 on Wednesday. The firm’s 50-day moving average is $160.77 and its two-hundred day moving average is $174.87. The company has a market capitalization of $5.15 billion, a price-to-earnings ratio of 59.84 and a beta of 0.87. Krystal Biotech has a 52 week low of $141.72 and a 52 week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.23. The company had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business’s revenue was up 116.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.30 EPS. On average, equities research analysts predict that Krystal Biotech will post 6.14 earnings per share for the current year.

Insider Buying and Selling

In related news, CAO Kathryn Romano sold 750 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the sale, the insider now owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. This represents a 1.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Krystal Biotech

A number of institutional investors have recently added to or reduced their stakes in the business. FMR LLC lifted its stake in Krystal Biotech by 0.5% in the fourth quarter. FMR LLC now owns 4,314,014 shares of the company’s stock valued at $675,833,000 after acquiring an additional 21,133 shares during the last quarter. Vanguard Group Inc. lifted its stake in Krystal Biotech by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company’s stock valued at $450,938,000 after acquiring an additional 28,707 shares during the last quarter. Avoro Capital Advisors LLC lifted its stake in Krystal Biotech by 0.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company’s stock valued at $411,831,000 after acquiring an additional 6,600 shares during the last quarter. State Street Corp lifted its stake in Krystal Biotech by 9.0% in the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after acquiring an additional 119,936 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Krystal Biotech by 2.0% in the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock valued at $107,714,000 after acquiring an additional 11,411 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).